Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Nuffield Department of Primary Care Health Sciences at the University of Oxford and the Royal College of General Practitioners (RCGP) have joined forces with clinical system supplier EMIS Health to urgently recruit as many GP practices as possible for COVID-19 research.

Today, the Oxford RCGP’s Research and Surveillance Centre (RSC) has written to nearly 4,000 GP practices in England using EMIS Health systems asking them to contribute patient data to help them develop a deeper understanding of the COVID-19 pandemic in general practice.

The data – shared under strict governance guidelines – will enable researchers to understand the spread of COVID-19, including tracking when it peaks and helping to inform government strategy around measures such as social distancing and lockdown. Practices are also being asked to support public health surveillance by supplying samples from symptomatic patients and providing extra blood samples from asymptomatic patients having routine blood tests. Some practices are also being asked to take part in rapid clinical trials of selected medicines to reduce the duration and severity of the virus. The first trial will need up to 3,000 patients. As many practices as possible are needed to support the work.

Professor Richard Hobbs, Head of Department of Primary Care Health Sciences said, 'This has been an extraordinary collaborative effort to compress many months of work into a few days. We are finalising the first national COVID-19 trial outside of hospital, led by Professor Chris Butler; significantly extending the only national surveillance of COVID-19 outside of hospitals; and considering efficient COVID-19 information feedback to practices.'

Read the full story on the Department of Primary Care Health Sciences website

This story is also featured on the University of Oxford website

Similar stories

Young lives under pressure as global crises hits mental health and well-being – report

The well-being and mental health of young people in low - and middle - income countries have been dramatically affected by the series of crises hitting the world. As the international community continues to struggle with the impact of COVID-19, conflict and climate change, the latest report from the Young Lives project shows a long-running upward trend in young people’s well-being has been sharply reversed alongside widespread anxiety and depression. Young people are less confident about their futures for the first time in the 20-year study.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

New tool aims to make bowel cancer treatments more effective

The Leedham Lab in Nuffield Department of Medicine (NDM) has been awarded over £2M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Doug Higgs awarded the 2023 Genetics Society Medal

The award recognises Radcliffe Department of Medicine's Professor Higgs major contribution to our understanding of how mammalian genes are switched on and off, and using haematopoiesis as a model to understand how genes function.

First evidence drug resistant bacteria can travel from gut to lung, increasing infection risks

A new Oxford University study released during World Antimicrobial Awareness Week has significant findings on how antimicrobial resistance (AMR) arises and persists. The results, published today in Nature Communications, provide the first direct evidence of AMR bacteria migrating from a patient’s gut microbiome to the lungs, increasing the risk of deadly infections.